3/9
08:54 am
actu
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors [Yahoo! Finance]
Medium
Report
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors [Yahoo! Finance]
3/9
08:45 am
actu
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Medium
Report
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
3/7
02:59 am
actu
Low
Report
3/4
05:00 pm
actu
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Medium
Report
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
2/24
09:18 am
actu
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/24
08:45 am
actu
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/14
01:32 am
actu
Actuate Therapeutics (NASDAQ:ACTU) was upgraded by analysts at
Wall Stre
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) was upgraded by analysts at
Wall Stre
1/21
08:45 am
actu
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Medium
Report
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
1/17
01:11 am
actu
Actuate Therapeutics (NASDAQ:ACTU) was downgraded by analysts at
Wall St
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) was downgraded by analysts at
Wall St
1/12
09:00 am
actu
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Low
Report
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
1/12
08:45 am
actu
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Medium
Report
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
1/6
08:45 am
actu
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Medium
Report
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
12/30
04:09 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/24
07:01 pm
actu
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
12/23
04:09 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.